Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

Related Keywords

United States ,Russia ,Ukraine ,America ,Paula Schwartz ,Andreas Muehler ,Jessica Breu ,Daniel Vitt ,Edna Kaplan ,Exchange Commission ,Rx Communications Group ,Nasdaq ,Immunic Inc Nasdaq ,Immunic Inc ,Unblinded Interim Biomarker Analysis Expected ,Full Data Readout Expected ,Chief Executive Officer ,Chief Medical Officer ,North America ,Eastern Europe ,Vidofludimus Calcium ,Private Securities Litigation Reform Act ,Annual Report ,Investor Relations ,Immunic ,Nc ,